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ABSTRACT
Objective: The objective of this study was to study the prevalence and severity of possible drug-drug interactions (DDIs) among the geriatric patients.
Methods: The present study was a retrospective cross-sectional study. Case records of geriatric inpatients from the medical records department 
were included in the study and the case records of all the remaining age group inpatients were excluded from the study. All the collected cases were 
subjected to check for the DDIs using the software Micromedex 2.0 and were categorized into minor, moderate, and major based on the severity.
Results: In this study, a total of 85 cases were screened for possible DDIs, and among them, 54 cases were found to be with 179 possible DDIs. The 
prevalence was observed to be 63.5%. Most of the possible DDIs were found to be with moderate severity (65.4%) followed by major (25.7%). 
Majority of the possible DDIs were observed in the Department of General Medicine (83.2%) followed by chest and tuberculosis (7.8%).
Conclusion: Majorly, the severity of interactions was found to be moderate in this study. To reduce the DDIs, rationale prescriptions have to be 
prescribed by considering the risk-benefit ratio. Geriatrics should be prescribed very cautiously because the age-related pharmacokinetics plays a 
significant role. By taking all the above aspects into consideration, clinical pharmacist should play a crucial role in the prevention and management 
of DDIs, especially in geriatrics.
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INTRODUCTION
Improving the health-related quality of life in geriatric patients is one 
of the significant challenges faced by the health-care fraternity [1,2]. 
When compared to younger individuals, individuals over the age of 
65 years are more likely to be on drug therapy. Usually, they used to 
be under polypharmacy due to comorbid disease conditions [3,4]. 
Polypharmacy is a significant risk factor in resulting the drug-
drug interactions (DDIs) [5-7]. A DDI can be defined as a clinically 
meaningful alteration in the effect of the object drug as a result of the 
coadministration of the precipitant drug [8-10]. Aging associated with 
altered drug pharmacokinetics contributes to DDIs that represent a 
considerable source of preventable harm in geriatric patients [11-15]. 
A recent study on the incidence and preventability of adverse drug 
events among the older persons in the ambulatory setting revealed 
that about 13% of preventable prescribing errors were involved with 
drug interactions [16]. According to a study in Finland, about 4.8% of 
the residents were observed to be with significant drug interactions 
clinically [17]. A higher prevalence of potentially harmful drug 
combinations (25%) was reported by a study from Taiwan in the year 
of 2008 [18]. In developing countries, little information is available 
about the prevalence of DDIs in geriatrics [19]. Hence, in this study, we 
made an attempt to assess the prevalence and severity of possible DDIs 
among the geriatric patients.
METHODS
The present study was a retrospective cross-sectional study, 
conducted at Konaseema Institute of Medical Sciences, Amalapuram, 
Andhra Pradesh, India. This study was approved by the Institutional 
Ethics Committee (No: 97/2015). Case records of the geriatric inpatients 
(≥65 years) from the medical records department were included in the 
study and the case records of all the remaining age group inpatients 
were excluded from the study. All the collected cases were subjected 
to check for the possible DDIs using the software Micromedex 2.0 
and were categorized into minor, moderate, and major based on the 
severity [17-20].
Statistical analysis
SPSS 21.0 was used to perform the statistical analysis. Chi-square test 
was performed and p value was obtained by two-tailed method at 95% 
confidence interval.
RESULTS
In our study, a total of 85 cases were screened for DDIs using the 
software. Among them, 54 cases were observed with 179 possible DDIs, 
and the prevalence was observed to be 63.5%. Table 1 represents the 
gender-wise categorization of the patients involved in the study and 
Fig. 1 represents the prevalence of drug-drug interactions.
Table 2 represents the age-wise categorization of the patients observed 
with possible interactions. Among the 54 cases observed with possible 
DDIs 35 (64.8%) were observed to be in the age group of 65–69 years, 
11 (20.4%) were in the age group of 70–74 years, 5 (9.3%) were in 
the age group of 75–79 years, and 3 (5.6%) were in the age group of 
80–84 years.
Fig. 2 graphically represents the type of polypharmacy observed 
among the prescriptions observed with possible DDIs. Among them, 
38  (70.4%)  were  observed  with  major  polypharmacy  (≥9  drugs), 
11 (20.4%) were observed with moderate polypharmacy (6–8 
drugs), and 5 (9.2%) were observed with minor polypharmacy (3–5 
drugs).
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Table 3 represents the severity of possible DDIs involved in the study. 
Among the 179 possible DDIs, 16 (8.9%) were found to be minor, 
117 (65.4%) were found to be moderate, and 46 (25.7%) were found 
to be major interactions.
Fig. 3 represents the department-wise categorization of possible DDIs 
among the geriatric patient population. Among the total possible DDIs 
observed in this study, 83.2% were observed in the Department of 
General Medicine, 7.8% were observed in the Department of Chest and 
Tuberculosis (TB), 4.5% were in the Department of Gynecology and 
Obstetrics, and again, 4.5% were in the Department of Orthopedics. 
Table 4 represents some of the frequently observed possible DDIs in 
this study.
DISCUSSION
DDIs are the significant subgroup of adverse drug events that are highly 
prevalent in geriatric patients. In this study, a total of 85 cases were 
screened for possible DDIs, and among them, 54 cases were found to 
be with possible DDIs. Among them, females (57.4%) were found to be 
with more number of possible DDIs when compared to males (42.6%). 
The prevalence was observed to be 63.5%. The prevalence of possible 
DDIs in the age group of 65–69 years (64.8%) was found to be high 
followed by the age group of 70–74 years (20.4%). This result was 
found to be differed from the study done by Rahmawati et al. as their 
study revealed very less prevalence (16%) of possible DDIs in the age 
group of 65–69 years [19].
Geriatric patients would be more prone to DDIs due to the age-
related physiologic changes and increased risk of developing diseases 
related to age when compared to younger patients. Polypharmacy 
can be observed in the prescriptions which were prescribed to treat 
the chronic diseases. In this study, the majority of the prescriptions 
were observed to be with major polypharmacy (70.4%) followed by 
moderate polypharmacy (20.4%) as geriatric patients were mainly 
observed with multiple disease conditions. Most of the possible 
DDIs were found to be with moderate severity (65.4%) followed by 
major (25.7%). Majority of the possible DDIs were observed in the 
Department of General Medicine (83.2%) followed by the chest and TB 
department (7.8%).
CONCLUSION
In this study, the prevalence of possible DDIs among the geriatrics was 
found to be 63.5%. Majority of the prescriptions were observed with 
major polypharmacy. Prescribing the drugs in geriatrics is a unique 
challenge and polypharmacy become a significant consideration. 
Polypharmacy became more common to manage the complex and 
chronic diseases in geriatrics, and thus, DDIs became a major concern 
in clinical practice. Majorly, the severity of interactions was found to 
be moderate in geriatrics in our study. To reduce the DDIs, rationale 
Table 1: Gender-wise categorization of patients involved in the study
Gender Cases observed with 
interactions (%)
Cases observed without 
interactions (%)
Total (%) χ2 value p value
Male 23 (42.6) 16 (51.6) 39 (45.9) 0.645 0.42
Female 31 (57.4) 15 (48.4) 46 (54.1)
Total 54 (100) 31 (100) 85 (100)
Table 2: Age-wise categorization of patients with drug-drug 
interactions
Age Male (%) Female (%) Total (%)
65–69 15 (65.2) 20 (64.5) 35 (64.8)
70–74 4 (17.4) 7 (22.6) 11 (20.4)
75–79 2 (8.7) 3 (9.7) 5 (9.3)
80–84 2 (8.7) 1 (3.2) 3 (5.6)
Total 23 (100) 31 (100) 54 (100)
Table 3: Severity of possible DDIs involved in the study
Severity Male (%) Female (%) Total (%) χ2 value p value
Minor 5 (6.9) 11 (10.3) 16 (8.9) 2.512 0.28
Moderate 52 (72.2) 65 (60.8) 117 (65.4)
Major 15 (20.9) 31 (28.9) 46 (25.7)
Total 72 (100) 107 (100) 179 (100)
DDIs: Drug-drug interactions
Fig. 1: Prevalence of possible drug-drug interactions among the 
geriatric patients
Fig. 2: Types of polypharmacy involved in the study
Fig 3: Department-wise categorization of possible drug-drug 
interactions among the geriatric patient population
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prescriptions have to be prescribed by considering the risk-benefit 
ratio. Geriatrics should be prescribed very cautiously because the age-
related pharmacokinetics plays a significant role. By taking all the above 
aspects into consideration, clinical pharmacist should play a crucial role 
in the prevention and management of DDIs in geriatrics especially.
LIMITATION
This study with a prospective type of approach along with the 
involvement of other health-care professionals would show a significant 
impact in screening the clinically encountered DDIs for providing the 
better pharmaceutical care for the patients by the direct involvement of 
the clinical pharmacist.
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Table 4: Examples of interactions observed in the study
Major interactions Moderate interactions Minor interactions
Metronidazole+Ondansetron Atorvastatin+Clopidogrel Aspirin+Phenytoin
Rifampicin+Phenytoin Dexamethasone+Rifampicin Bisacodyl+Ranitidine
Ciprofloxacin+Metronidazole Ciprofloxacin+Diclofenac Isoniazid+Theophylline
